NACTx regimens containing anthracyclines and taxanes are generally used in the neoadjuvant treatment of breast cancer, and trastuzumab ± pertuzumab is added to the treatment in the case of HER2(+) disease [10,11]. Here, ERBB2 is linked to breast carcinoma.